tiprankstipranks
Bellicum Pharmaceuticals Asset Sale and Dissolution Vote Adjourned
Company Announcements

Bellicum Pharmaceuticals Asset Sale and Dissolution Vote Adjourned

Bellicum Pharmaceuticals (BLCM) has released an update.

Don't Miss our Black Friday Offers:

Bellicum Pharmaceuticals, Inc. held a special meeting of stockholders on January 24, 2024, to approve the sale of certain assets to MD Anderson Cancer Center and the company’s subsequent dissolution, as per the Delaware General Corporation Law. The meeting was adjourned due to a lack of quorum, with a reconvened meeting set for February 20, 2024. Stockholders are encouraged to vote on both proposals, with no changes to the proposals on the reconvened meeting agenda. The company continues to solicit votes and has informed stockholders to consult the previously furnished Information Statement for details.

For further insights into BLCM stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
TipRanks Auto-Generated NewsdeskBellicum Pharmaceuticals Appoints New CEO During Dissolution
TipRanks Auto-Generated NewsdeskBellicum Pharmaceuticals Finalizes Sale and Approves Dissolution
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App